NCT02211118View on ClinicalTrials.gov

Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

April 30, 2016

Conditions
COPDSedationDexmedetomidine
Interventions
DRUG

Intranasal dexemdetomidine (IN-DEX)

Trial Locations (1)

45428

Dayton VA Medical Center, Dayton

All Listed Sponsors
lead

Dayton VA Medical Center

FED

NCT02211118 - Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD | Biotech Hunter | Biotech Hunter